We performed susceptibility testing for eravacycline in comparison to 4 other antimicrobials against 10 , 40 , 44 , 20 , and 20 isolates. All eravacycline MICs were ≤0.25 μg/ml, except that for one isolate of , for which the MIC was 2 μg/ml. Eravacycline was markedly more potent than tetracycline, azithromycin, moxifloxacin, and clindamycin against all isolates tested, which included 37 macrolide, tetracycline, and/or fluoroquinolone-resistant organisms.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7526834 | PMC |
| http://dx.doi.org/10.1128/AAC.00698-20 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
RamA upregulates the ATP-binding cassette transporter to mediate resistance to tetracycline-class antibiotics and the stability of membranes in .
Microbiol Spectr
December 2024
Institute of Antibiotics, Huashan Hospital, Fudan University, Shanghai, China.
Article Synopsis
- RamA is a crucial regulator in bacteria, enhancing resistance to tetracycline-class antibiotics by activating the operon responsible for multidrug resistance.
- The deletion of RamA leads to significantly reduced transcription levels of this operon, while restoring RamA reinstates normal function.
- The study highlights RamA's role in bacterial membrane stability and suggests potential pathways for developing new antimicrobial treatments against resistant strains.
Discordant Susceptibilities of Enterobacterales to Different Tetracycline Classes.
Cureus
December 2024
Internal Medicine, University of Maryland Medical Center, Baltimore, USA.
When bacteria are tetracycline- or doxycycline-resistant, the ability of these bacteria to be susceptible to the other tetracyclines is not well defined. Consequently, gaining knowledge about the ability to infer Enterobacterales susceptibility to minocycline and third-generation tetracycline antibiotics from surrogates is vital. In this study, we show that tigecycline may be a reasonable surrogate from which clinicians can infer omadacycline and eravacycline susceptibilities, even in the presence of doxycycline and tetracycline resistance.
View Article and Find Full Text PDFActivity of cefiderocol in combination with tetracycline analogues against carbapenem-resistant Acinetobacter baumannii.
J Antibiot (Tokyo)
December 2024
Department of Respiratory Medicine, An Qiu People's Hospital, An Qiu, China.
Therapeutic options for carbapenem-resistant Acinetobacter baumannii (CA-AB) are quite limited. Cefiderocol, a novel siderophore cephalosporin, has shown potent in vitro activity against CR-AB, and new tetracycline analogues such as eravacycline and omadacycline have been available in recent years. However, the synergism of cefiderocol with tetracycline analogues against CR-AB has not been well investigated.
View Article and Find Full Text PDFActivity and resistance mechanisms of the third generation tetracyclines tigecycline, eravacycline and omadacycline against nationwide Spanish collections of carbapenemase-producing Enterobacterales and Acinetobacter baumannii.
Biomed Pharmacother
December 2024
Servicio de Microbiología and Instituto de Investigación Biomédica A Coruña (INIBIC), Complexo Hospitalario Universitario A Coruña (CHUAC), A Coruña, Spain; Ciber de Enfermedades Infecciosas (CIBERINFEC), Instituto de Salud Carlos III, Madrid, Spain.
Introduction: The rise in multidrug-resistant bacteria challenges clinical microbiology. Tigecycline, eravacycline, and omadacycline show promise against carbapenem-resistant Enterobacterales and Acinetobacter baumannii. This study evaluates their activity and resistance mechanisms.
View Article and Find Full Text PDFactivities of eravacycline against clinical bacterial isolates: a multicenter study in Guangdong, China.
Front Microbiol
November 2024
Department of Clinical Laboratory, The Seventh Affiliated Hospital, Sun Yat-sen University, Shenzhen, China.
Introduction: Eravacycline (ERV), a novel tetracycline derivative, exhibits broad-spectrum antibacterial activity, but data on the bacterial activity against Chinese bacterial isolates are very scarce. This study aims to evaluate the activity of eravacycline against the common Gram-positive and Gram-negative bacteria isolates in Guangdong, China.
Methods: The clinical isolates were collected from four centers between 1 November 2023 and 31 January 2024, and the susceptibility of eravacycline (MIC, MIC, and MIC) was determined using broth microdilution as a reference method and E-TEST strips to evaluate their consistency.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!